New research presented this week at the American Academy of Orthopaedic Surgeons annual meeting suggests a potential link between prolonged utilize of GLP-1 receptor agonists – medications like semaglutide and liraglutide commonly prescribed for weight loss and type 2 diabetes – and decreased bone density. While observational, these findings warrant further investigation given the widespread adoption of these drugs.
The increasing prevalence of obesity and type 2 diabetes globally has led to a surge in the prescription of GLP-1 receptor agonists (GLP-1 RAs). These medications mimic the effects of glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and blood sugar. While celebrated for their efficacy in promoting weight loss and improving metabolic health, emerging data raises concerns about potential long-term musculoskeletal effects. This is particularly relevant as millions of individuals now rely on these drugs for chronic disease management, and five-to-ten year follow-up data is only now becoming available.
In Plain English: The Clinical Takeaway
- Bone Health & Weight Loss Drugs: New studies suggest that medications used for weight loss, like Ozempic and Wegovy, *might* slightly weaken bones over time.
- It’s Not Just the Drug: The effect on bones could be due to the medication itself, the rapid weight loss it causes, or existing health conditions like diabetes.
- What You Can Do: Talk to your doctor about getting enough protein, calcium, and vitamin D, and doing strength-training exercises to protect your bones while taking these medications.
The GLP-1 Mechanism and Bone Remodeling
GLP-1 RAs exert their effects by binding to GLP-1 receptors located throughout the body, including the pancreas, brain, and gastrointestinal tract. This binding stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying, ultimately leading to reduced appetite and weight loss. Still, GLP-1 receptors are as well present on osteoblasts and osteoclasts – the cells responsible for bone formation and resorption, respectively. The precise mechanism by which GLP-1 RAs might impact bone metabolism is still under investigation, but it’s hypothesized that alterations in GLP-1 signaling could disrupt the delicate balance of bone remodeling. Specifically, some research suggests GLP-1 signaling may favor osteoclast activity, leading to increased bone resorption. [1]
Study Findings and Epidemiological Context
The study presented at the AAOS meeting analyzed data from over 146,000 adults with obesity and type 2 diabetes over a five-year period. Researchers observed that approximately 4% of patients taking GLP-1 medications developed osteoporosis, compared to just over 3% of those not on the medication. Osteomalacia, or softening of the bones, was roughly twice as prevalent in the GLP-1 user group (0.2% vs. 0.1%), and gout rates were slightly elevated (7.4% vs. 6.6%). These findings, while observational, are consistent with smaller studies suggesting a potential link between GLP-1 RA use and reduced bone mineral density.
It’s crucial to contextualize these findings within broader epidemiological trends. Osteoporosis affects an estimated 10.2 million Americans aged 65 and older, with women being disproportionately affected. [2] The observed increase in osteoporosis risk among GLP-1 users, while statistically significant, represents a relatively minor absolute risk increase. However, given the millions of individuals now using these medications, even a small increase in risk could translate to a substantial public health impact.
Regulatory Landscape and Geographic Impact
The findings are currently under review by regulatory bodies worldwide. In the United States, the Food and Drug Administration (FDA) is actively monitoring post-market surveillance data for GLP-1 RAs, including reports of musculoskeletal adverse events. The European Medicines Agency (EMA) is also conducting a similar review. These agencies will likely require manufacturers to conduct further studies to definitively assess the long-term impact of GLP-1 RAs on bone health.
Access to bone density screenings (DEXA scans) varies significantly across healthcare systems. In the UK, the National Health Service (NHS) provides DEXA scans to individuals at high risk of osteoporosis, but waiting times can be substantial. The increased awareness of potential bone health risks associated with GLP-1 RAs may lead to increased demand for these screenings, potentially straining already overburdened healthcare resources.
Funding and Bias Transparency
The study presented at the AAOS meeting was funded by an unrestricted research grant from the American Academy of Orthopaedic Surgeons. While the funding source does not inherently invalidate the findings, it’s important to acknowledge potential biases. The researchers have disclosed no conflicts of interest. Further independent research, funded by diverse sources, is needed to confirm these findings and elucidate the underlying mechanisms.
Expert Perspectives
“We are only beginning to notice the five- and ten-year follow-up data for patients on GLP-1 medications. Any drug that sees this rapid uptake needs careful scrutiny, particularly in orthopedics where obesity and surgery often go hand in hand.” – Muaaz Wajahath, Michigan State University College of Human Medicine.
“The cardiovascular benefits of GLP-1s are robust, and for high-risk patients, those benefits are substantial and often life-saving. The metabolic and cardiovascular advantages still outweigh a modest increase in fracture or gout risk, provided these risks are monitored and mitigated by healthcare providers.” – Dr. Fernando Ovalle Jr., Obesity Medicine Specialist.
Data Summary: GLP-1 RA Use and Musculoskeletal Outcomes
| Outcome | GLP-1 RA Users (%) | Non-Users (%) |
|---|---|---|
| Osteoporosis | 4.0 | 3.1 |
| Osteomalacia | 0.2 | 0.1 |
| Gout | 7.4 | 6.6 |
Contraindications & When to Consult a Doctor
Individuals with pre-existing conditions affecting bone health – such as osteoporosis, osteopenia, or a history of fractures – should discuss the potential risks and benefits of GLP-1 RAs with their healthcare provider. Women post-menopause and older adults are also at higher risk and should be closely monitored. If you experience new bone pain, joint pain, or an increased frequency of fractures while taking a GLP-1 RA, seek immediate medical attention. Anyone experiencing acute gout flares should consult their physician for appropriate management.
The long-term implications of GLP-1 RA use on bone health remain uncertain. While the current evidence suggests a potential association, further research is needed to establish causality and identify strategies to mitigate any potential risks. A proactive approach, including regular bone density screenings, adequate calcium and vitamin D intake, and weight-bearing exercise, is crucial for individuals using these medications. The benefits of GLP-1 RAs in managing obesity and type 2 diabetes are undeniable, but a comprehensive assessment of their potential musculoskeletal effects is essential to ensure optimal patient care.
References
- [1] Li, Y., et al. “GLP-1 receptor agonists and bone metabolism: A systematic review and meta-analysis.” *Journal of Bone and Mineral Metabolism* 41.8 (2023): 1613-1624.
- [2] National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Osteoporosis.” Accessed April 1, 2026.
- [3] American Academy of Orthopaedic Surgeons. “GLP-1 Receptor Agonist Impact on Fracture Risk in Patients with Obesity.” November 20, 2025.
- [4] U.S. Food and Drug Administration. Accessed April 1, 2026.
- [5] European Medicines Agency. Accessed April 1, 2026.
